Researchers at CureLab Oncology, a sister company of CureLab Veterinary, have partnered with colleagues at the University of Camerino (Italy) to test the feasibility of using p62 protein as a target for anti-cancer immune therapies in cats.
The results were published in Animals in a paper tited, “Immunohistochemical Expression of p62 in Feline Mammary Carcinoma and Non-Neoplastic Mammary Tissue.” Animals is an international, peer-reviewed, open-access journal devoted entirely to animals, including zoology and veterinary sciences, published semimonthly online by MDPI.
To be a cancer-specific target for immune therapies, a protein must be overexpressed in a tumor compared to normal tissue. Immunohistochemical analysis of mammary tissues from feline neoplasia compared to normal mammary tissues revealed that in cats, just as in humans, mammary tumors possess higher levels of p62 protein.
These results also support testing new anti-cancer medicine in cats diagnosed with spontaneous tumors as a model for future human oncology applications, and the associated comparative medicine value of feline models.
Soon, CureLab Veterinary will begin testing its lead product, Elenavet, for the treatment of feline (and canine) cancers, as well as for non-cancerous diseases of chronic inflammation.